Head

Full year trading update and notice of results

Retrieved on: 
Friday, May 3, 2024
Molten Ventures, Investment, Euronext Dublin, NAV, Health, GRW, EIS, Euro, Environment, Acquisition, PLC, Head, VCT, FX, Calendar, Bank

Gross Portfolio Value (“GPV”) (unaudited) is expected to be circa £1,377 million (31 March 2023: £1,299 million).

Key Points: 
  • Gross Portfolio Value (“GPV”) (unaudited) is expected to be circa £1,377 million (31 March 2023: £1,299 million).
  • Uplifts in fair value from the acquisition of Forward Partners and the investment stake in Seedcamp’s Fund III.
  • Realisations generated cash proceeds for Molten in the year of £39 million (year to 31 March 2023: £48 million).
  • These aside, valuations across both our Core and Emerging portfolio assets have held essentially flat in aggregate in the second half.

VVV Resources Limited: Appointment of New Director and Issue of Shares in Lieu of Directors Fees

Retrieved on: 
Friday, May 3, 2024
School, Law, Bar Professional Training Course, Court of cassation, Bias, Traction, Ageing, Inn, Ontogeny, Law school, Gray's Inn, Natural Resources, Senior advisor, VVV, Head

VVV Resources Plc, 100% owner of the Mitterberg Copper Project in Austria, is pleased to announce the appointment of Benjamin (Ben) Samuel Hill as a Non-Executive Director of the Company with immediate effect.

Key Points: 
  • VVV Resources Plc, 100% owner of the Mitterberg Copper Project in Austria, is pleased to announce the appointment of Benjamin (Ben) Samuel Hill as a Non-Executive Director of the Company with immediate effect.
  • Ben, aged 48, is skilled in equity and quasi equity financing with demonstrable experience in structuring and public and private equity investing.
  • Ben continues to advise a number of family offices providing them with deal flow, structuring and investment advice.
  • Jim Williams, Executive Chairman of VVV Resources, commented: “On behalf of Mahesh Pulandaran and myself, we are delighted that Ben is joining us at VVV Resources.

Spires Connect Launched: Revolutionising Growth for Tutoring Agencies

Retrieved on: 
Thursday, May 2, 2024
Online, Education, Head, Oxbridge, Statistics, Trustpilot, API, Growth, University, Trust, Student, Connect, Tutoring

Today, it takes a giant leap forward with Spires Connect, aimed at transforming the operational efficiency and brand expansion of tutoring agencies.

Key Points: 
  • Today, it takes a giant leap forward with Spires Connect, aimed at transforming the operational efficiency and brand expansion of tutoring agencies.
  • Spires Connect is designed to revolutionise the online tutoring industry, offering agencies a seamless route to scale their services and enhance client retention significantly.
  • Spires Connect addresses these issues head-on by allowing agencies to host a sophisticated tutoring marketplace under their brand, eliminating administrative burdens and enhancing the teaching focus for tutors.
  • Dr. Leo Evans, Spires Founder and CEO, shares his vision: “Launching Spires Connect marks a significant milestone in our journey to redefine the tutoring landscape.

Kura Oncology Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
FDA, Cancer, KURA, Investment, Venetoclax, HNSCC, Food, Prognosis, Research, Renal cell carcinoma, FTI, AML, Webcast, Disease, LDAC, Patient, Azacitidine, QT interval, BTD, Acute myeloid leukemia, FLT3, Head, Initiate, ID, Breakthrough therapy, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2024 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2024 were $36.3 million, compared to $25.2 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $18.2 million, compared to $11.4 million for the first quarter of 2023.
  • ET / 1:30 p.m. PT today, May 2, 2024, to discuss the financial results for the first quarter 2024 and to provide a corporate update.

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Retrieved on: 
Friday, April 26, 2024
Cloud, Goldman Sachs, Yale University, Platform, Jefferies, Virology, Artificial intelligence, Information technology, Policy, Corporate development, MetLife, Senior, Therapy, Microsoft, Jefferies Group, Neurology, Mobility, Customer, CIO, Bank statement, Drug discovery, Biotechnology, Organization, Head, MSIM

The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access.

Key Points: 
  • The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access.
  • WARREN, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
  • Second, I’d like to reflect on our recent leadership appointments and the newly launched initiative in Artificial Intelligence (AI).
  • Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Retrieved on: 
Thursday, April 25, 2024
FDA, Patient, Cancer, Food, Pembrolizumab, Infection, ASCO, Arenavirus, PRIME, Society, Head, Annual general meeting, European Medicines Agency, OPSCC, Pharmaceutical industry

The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration (FDA) following the Company’s Type C meeting with the FDA.

Key Points: 
  • The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration (FDA) following the Company’s Type C meeting with the FDA.
  • The presentation will include data for approximately 40 head and neck cancer patients treated with HB-200 in combination with pembrolizumab.
  • We believe our trial design and alignment with our primary regulators can help us reach a potential registration more quickly.
  • The trial is expected to enroll approximately 250 patients across the seamless Phase 2/3 design.

New Benevity data shows companies that embrace an ‘impact mindset’ are building resilience in a polarized world

Retrieved on: 
Thursday, April 25, 2024
DEI, Erg, Volunteering, Social, Learning, AI, HR, CSR, Biophysical environment, Khosla, Culture, ESG, Marketing, Natural Resources, Head, ERG, Benevity, Management

, the company’s flagship conference, which brings together more than 700 purpose-driven professionals to share insights and strategies about the future of social impact.

Key Points: 
  • , the company’s flagship conference, which brings together more than 700 purpose-driven professionals to share insights and strategies about the future of social impact.
  • By helping companies scale the power of grassroots networks to drive inclusive workplaces they are adding tangible value to the business.
  • Four out of five companies say that ERGs are increasing in significance, and more than half are increasing their ERG budgets.
  • “The early 2020s were marked by companies highly focused on responding to crises, which shifted budgets and approaches to granting.

Less than half of veterinary professionals feel their profession is appreciated

Retrieved on: 
Thursday, April 25, 2024
Corporate headquarters, Food safety, Agriculture, Poultry, Head, Boehringer Ingelheim, Risk, Pet, AVMA, Veterinarian, Health, Animal, Infection, Horse, Research, Vaccine, Farmer, Cat, Human, Mental health, Livestock, Interface (computing), Pig, Dog, Boehringer, Organization, Veterinary medicine

World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.

Key Points: 
  • World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
  • Veterinary associations and Boehringer Ingelheim unite to help address this issue—starting with showcasing often-unseen aspects of the veterinary profession.
  • A main finding of the study is that only 49% of veterinarians feel that the veterinary profession in general is appreciated.
  • It truly is a vocation to aspire to.”
    Perceived levels of appreciation for the veterinary profession were relatively consistent across key types of veterinary teams — with only 48% of pet-focused (cats and dogs), 55% of livestock and 42% of equine veterinary professionals reporting that their profession was appreciated.

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, April 24, 2024
PFS, CMO, AMF, Cash, Pancreatic cancer, Research, Webcast, Lung, RT, AACR, Lung cancer, EIB, Conference call, Annual report, NBTXR3, ESMO, Conference, Janssen, NSCLC, Monroe Dunaway Anderson, Survival, Johnson & Johnson, Research and development, OS, Therapy, Neoplasm, Clinical trial, Cancer, Esophageal cancer, Immunotherapy, MD, Administration, University, URD, Patient, NANO, MD Anderson Cancer Center, Head, Bank statement, Growth, Pharmaceutical industry

PARIS and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document (URD) for the financial year ended December 31, 2023 with the French financial market authority (Autorité des marchés financiers or AMF), as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • “2023 was an incredible year of progress for Nanobiotix and our NBTXR3 program.
  • “During 2023, we reported prolonged survival from Study 102 in head and neck cancer further reinforcing the design of our ongoing pivotal NANORAY-312 trial.
  • Cash and Cash Equivalents: As of December 31, 2023, Nanobiotix had €75.3 million in cash and cash equivalents, compared to €41.4 million as of December 31, 2022.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and an update on business activities before taking questions from participants.

JAKKS Pacific Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, April 24, 2024
Head, Super Mario, News, Traction, Webcast, Costume, The Little Mermaid, Jakks Pacific, EPS, Adjustment, GAAP

SANTA MONICA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- JAKKS Pacific, Inc. (NASDAQ: JAKK) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SANTA MONICA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- JAKKS Pacific, Inc. (NASDAQ: JAKK) today reported financial results for the first quarter ended March 31, 2024.
  • Without that new news in Spring 2024, from a shipping and retail sales perspective, we experienced lower levels of both as anticipated.
  • For the first time in many years, there are no lenders or other parties restricting the common stockholders’ claim over the entire enterprise and its financial results.
  • In addition, the Company believes that the presentation of these financial measures enhances an investor’s ability to make period-to-period comparisons of the Company’s operating results.